Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Tagawa, Michihito ^a   Maekawa, Naoya ^b   Konnai, Satoru ^b   Takagi, Satoshi ^b  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR;

ANGIOSARCOMA; ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOG; FEMALE; HISTIOCYTIC SARCOMA; LUNG ADENOCARCINOMA; MALE; MELANOMA; NONHUMAN; OSTEOSARCOMA; PERIPHERAL LYMPHOCYTE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECTUM CARCINOMA; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY; UPREGULATION; ANIMAL; DOG DISEASE; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE; METABOLISM; PATHOPHYSIOLOGY; VETERINARY;

ANIMALS; ANTIGENS, CD28; CTLA-4 ANTIGEN; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION; HISTIOCYTIC SARCOMA; LYMPHOCYTES; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84960539636     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150030     Document Type: Article

References (39)

1. Fulmer AR, Mauldin GE. Canine histyocytic neoplasia: an overview. Can Vet J. 2007; 48: 1041-1050. PMID: 17987966
2. Moore PF, Affolter VK, Vernau W. Canine hemophagocytic histiocytic sarcoma: A proliferative disorder of CD11d+ macrophages. Vet Pathol. 2006; 43: 632-645. PMID: 16966440
3. Takahashi M, Tomiyasu H, Hotta E, Asada H, Fukushima K, Kanemoto H, et al. Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan. J Vet Med Sci. 2014; 76: 661-666. PMID: 24441652
4. Craig LE, Julian ME, Ferracone JD. The diagnosis and prognosis of synovial tumors in dogs: 35 cases. Vet Pathol. 2002; 39: 66-73. PMID: 12102220
5. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, et al. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med. 2007; 21: 121-126. PMID: 17338159
6. Rassnick KM, Moore AS, Russell DS, Northrup NC, Kristal O, Bailey DB, et al. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet Intern Med. 2010; 24: 1528-1531. PMID: 21155191
7. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005; 23: 515-548. PMID: 15771580
8. Wülfing C, Tunbridge HM, Wraith DC. New inhibitory signaling by CTLA-4. Nat Immunol. 2014; 15: 408-409.
9. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004; 4: 336-347. PMID: 15122199
10. Folkl A, Bienzle D. Structure and function of programmed death (PD) molecules. Vet Immunol Immunopathol. 2010; 15: 33-38.
11. Moore PF. A review of histiocytic diseases of dogs and cats. Vet Pathol. 2014; 51: 167-184.
12. Yamazaki H, Takagi S, Oh N, Hoshino Y, Hosoya K, Okumura M. Comparative analysis of mRNA expression of surface antigens between histiocytic and nonhistiocytic sarcoma in dogs. J Vet Intern Med. 2014; 28: 204-210. doi: 10.1111/jvim.12244 PMID: 24428323
13. Nielsen LN, Kjelgaard-Hansen M, Kristensen AT. Monocyte chemotactic protein-1 and other inflammatory parameters in Bernese Mountain dogs with disseminated histiocytic sarcoma. Vet J. 2013; 198: 424-428. doi: 10.1016/j.tvjl.2013.07.030 PMID: 23992872
14. Nielsen LN, McEvoy F, Jessen LR, Kristensen AT. Investigation of a screening programme and the possible identification of biomarkers for early disseminated histiocytic sarcoma in Bernese Mountain dogs. Vet Comp Oncol. 2012; 10: 124-134. doi: 10.1111/j.1476-5829.2011.00285.x PMID: 22235831
15. Friedrichs KR, Thomas C, Plier M, Andrews GA, Chavey PS, Young KM. Evaluation of serum ferritin as a tumor marker for canine histiocytic sarcoma. J Vet Intern Med. 2010; 24: 904-911. doi: 10.1111/j. 1939-1676.2010.0543.x PMID: 20561186
16. Choi SY, Sohn MH, Kwon BC, Kim KE. CTLA-4 expression in T cells of patients with atopic dermatitis. Pediatr Allergy Immunol. 2005; 16: 422-427. PMID: 16101935
17. Ayukawa H, Matsubara T, Kaneko M, Hasegawa M, Ichiyama T, Furukawa S. Expression of CTLA-4 (CD152) in peripheral blood T cells of children with influenza virus infection including encephalopathy in comparison with respiratory syncytial virus infection. Clin Exp Immunol. 2004; 137: 151-155. PMID: 15196256
18. Salazar-Fontana LI, Sanz E, Mérida I, Zea A, Sanchez-Atrio A, Villa L, et al. Cell surface CD28 levels define four CD4+ T cell subsets: abnormal expression in rheumatoid arthritis. Clin Immunol. 2001; 99: 253-265. PMID: 11318597
19. Kol R, Friedländer M, Riklis E, Raveh D. Separation of human lymphocytes on Ficoll-Paque gradients: stimulation of cells and depletion of a concanavalin-A responsive radioresistant subpopulation. Radiat Res. 1983; 95: 108-115. PMID: 6878623
20. Sakai M, Otani I, Ishigaki K, Edamura K, Takahashi T, Koie H, et al. Phenotypic analysis of hepatic T lymphocytes in a dog with chronic hepatitis. J Vet Med Sci. 2006; 68: 1219-1221. PMID: 17146184
21. Graves SS, Stone DM, Loretz C, Peterson LJ, Lesnikova M, Hwang B, et al. Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation. Transplantation. 2011; 91: 833-840. doi: 10.1097/TP.0b013e31820f07ff PMID: 21343872
22. Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Petersen CA. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol. 2013; 191: 5542-5550. doi: 10.4049/jimmunol.1301810 PMID: 24154626
23. Gardner D, Jeffery LE, Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant. 2014; 14: 1985-1991. doi: 10.1111/ajt.12834 PMID: 25098238
24. Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol. 2012; 2012:926321. doi: 10.1155/2012/926321 Epub 2012 Feb 12. PMID: 22500111
25. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133. doi: 10.1056/NEJMoa1302369 PMID: 23724867
26. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013; 19: 5300-5309. doi: 10.1158/1078-0432.CCR-13-0143 PMID: 24089443
27. Salazar-Fontana LI, Sanz E, Mérida I, Zea A, Sanchez-Atrio A, Villa L, et al. Cell surface CD28 levels define four CD4+ T cell subsets: abnormal expression in rheumatoid arthritis. Clin Immunol. 2001; 99: 253-265. PMID: 11318597
28. Brzezińska A, Magalska A, Szybińska A, Sikora E. Proliferation and apoptosis of human CD8(+)CD28 (+) and CD8(+)CD28(-) lymphocytes during aging. Exp Gerontol. 2004; 39: 539-544. PMID: 15050288
29. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 2006; 212: 131-148. PMID: 16903911
30. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271: 1734-1736. PMID: 8596936
31. Tosti G, Cocorocchio E, Pennacchioli E. Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol. 2013; 17: 245-256.
32. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723. doi: 10.1056/NEJMoa1003466 PMID: 20525992
33. Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol. 2013; 107: 517-522. doi: 10.1002/jso.23281 PMID: 23129549
34. Callahan MK, Wolchok JD. At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013; 94: 41-53. doi: 10.1189/jlb.1212631 PMID: 23667165
35. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677-704. doi: 10.1146/annurev.immunol.26.021607.090331 PMID: 18173375
36. Li J, Wang Z, Mao K, Guo X. Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer. Oncol Lett. 2014; 8: 1682-1686. PMID: 25202391
37. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with nonsmall cell lung cancer (NSCLC). Lung Cancer. 2012; 77: 306-311. doi: 10.1016/j.lungcan.2012.04.011 PMID: 22608141
38. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005; 19: 1788-1793. PMID: 16094420
39. Jaberipour M, Habibagahi M, Hosseini A, Habibabad SR, Talei A, Ghaderi A. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010; 16: 547-551. doi: 10.1007/s12253-010-9256-8 PMID: 20306312